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Background and Purpose Both platelet activation and lipid peroxidation
 
are potential sources of vasoactive eicosanoids that can be
 
produced via 
the cyclooxygenase pathway, ie, thromboxane (TX)
 
A2, or by free 
radical–catalyzed peroxidation of arachidonic acid, ie, isoprostanes. We 
investigated the biosynthesis of
 
TXA2 and F2-isoprostanes, as reflected 
by the urinary excretion of
 
11-dehydro-TXB2 and 8-epi-prostaglandin 
(PG) F2 , respectively,
 
in 62 consecutive patients (30 men, 32 women; 
mean age, 67±14
 
years) with acute ischemic stroke.
 
 
Methods At least two consecutive 6-hour urine samples were obtained
 
during the first 72 hours 
after onset of symptoms. Urinary eicosanoids
 
were measured by previously described 
radioimmunoassays.
 
 
Results Repeated periods of enhanced thromboxane biosynthesis
 
were found in 52% of patients. 
Urinary 11-dehydro-TXB2 averaged
 
221±207 (mean±SD; n=197; range, 13 to 967) pmol/mmol
 
creatinine in 30 patients treated with cyclooxygenase inhibitors (mostly
 
aspirin) at the time of 
study versus 392±392 (n=186;
 
range, 26 to 2533) in 32 untreated patients (P<.001). The 
corresponding
 
values for 8-epi-PGF2  excretion were 74±42 (range, 14
 
to 206) and 83±65 
(range, 24 to 570) pmol/mmol creatinine
 
(P>.05). The correlation between the two metabolites 
was
 
moderate in both untreated patients (r=.41, P<.001) and patients
 
with cyclooxygenase 
inhibitors (r=.31, P<.001). In a multiple
 
regression analysis, increased thromboxane production 
was independently
 
associated with severity of stroke on admission, atrial fibrillation,
 
and 
treatment with cyclooxygenase-inhibiting drugs.
 
 
Conclusions We conclude that during the first few days after
 
an acute ischemic stroke (1) platelet 
activation occurs repeatedly
 
in a cyclooxygenase-dependent fashion; (2) platelet activation
 
is not 
associated with concurrent changes in isoprostane biosynthesis;
 
(3) platelet activation is 
independently associated with stroke
 
severity and atrial fibrillation; and (4) isoprostane 
biosynthesis
 
is largely independent of platelet cyclooxygenase activity.
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Both platelet activation and lipid peroxidation are potential
 
sources of 
vasoactive eicosanoids that can be produced via the cyclooxygenase
 
pathway, ie, TXA2, or by free radical–catalyzed peroxidation
 
of 
arachidonic acid, ie, isoprostanes. In previous studies we
 
reported 
enhanced thromboxane biosynthesis, reflected by the
 
urinary excretion of 
a major thromboxane metabolite, 11-dehydro-TXB2,
 
in patients with 
acute stroke.
1
 
2
 Thromboxane production could
 
be largely suppressed by 
low-dose aspirin, suggesting its cyclooxygenase-dependent
 
formation in platelets. The F2-
isoprostanes, a family of prostaglandin
 
isomers, are free radical–catalyzed products of 
arachidonic
 
acid metabolism, of which in vivo formation in humans was first reported
 
by 
Morrow et al.
3
 They are initially formed in situ on phospholipids,
 
from which they are 
subsequently released, preformed presumably
 
by phospholipases.
4
 They circulate in plasma and 
are excreted
 
in urine.
5
 
6
 Among the F2-isoprostanes, 8-epi-PGF2  is one of
 
the most abundantly 
formed under physiological conditions.
5 
It was shown to be a potent vasoconstrictive agent in 
animal models
 
in both renal
3
 
7
 and pulmonary vessels.
8
 
9
 Furthermore, 8-epi-PGF2
 
was found to 
cause platelet shape change but not aggregation.
10 11
 Increased plasma levels of F2-isoprostanes 
were found in smokers,
12 
in patients with the hepatorenal syndrome,
13
 and in patients
 
with non–
insulin-dependent diabetes mellitus.
14
 Increased
 
urinary 8-epi-PGF2  levels were found in 
healthy smokers,
15
 after acetaminophen overdose,
16
 in patients treated with thrombolytic
 
therapy 
for acute myocardial infarction,
16
 and in hypercholesterolemia.
17 
Since F2-isoprostanes are 
formed by means of free radical–catalyzed peroxidation of arachidonic acid, it is suggested that 
an increased
 
production may be a reflection of oxidative stress in these
 
different clinical 
conditions. However, recent studies suggest
 
that relatively small amounts of 8-epi-PGF2  can 
also be formed
 
in a cyclooxygenase-dependent manner.
16
 
18
 
19
 
20
 It is not
 
known to what extent 
urinary excretion of 8-epi-PGF2  reflects biosynthesis
 
in the vasculature, since no dose-response 
infusion studies
 
have yet been performed to assess its fractional elimination. Moreover,
 
the 
metabolism in humans has been only incompletely characterized.
21 
 
In patients with ischemic stroke, both activation of platelet
 
and monocyte cyclooxygenases
20
 and 
the free radical–catalyzed pathway are potential sources of 8-epi-PGF2  formation. Moreover,
 
by 
its potential effect on vessel walls and platelets, this
 
eicosanoid may have a negative influence on 
stroke outcome.
 
 
To investigate the actual rate of 8-epi-PGF2  biosynthesis in
 
vivo, we studied the urinary 
excretion of this prostaglandin
 
in patients with acute ischemic stroke. In addition, we related
 
the 
production of 8-epi-PGF2  to thromboxane biosynthesis, as
 
reflected by urinary 11-dehydro-
TXB2 production. Finally, we
 
evaluated the effect of cyclooxygenase inhibition on the 
production of
 
both eicosanoids.
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Study Patients 
We prospectively studied 62 consecutive patients (30 men and
 
32 
women; mean age, 67±14 years) with acute ischemic
 
stroke who were 
admitted to the Dijkzigt University Hospital
 
Rotterdam and were 
included in the Rotterdam Stroke Databank
 
between March and 
December 1994. The University Hospital Rotterdam
 
is an area hospital 
serving an urban population. This center
 
has no specific selection criteria 
for the admission of stroke
 
patients; however, young stroke patients are referred more frequently
 
to this center than to the nonacademic centers in the region.
 
 
All patients were screened according to a strict protocol consisting
 
of a full neurological 
examination, standardized blood tests,
 
at least one and usually two CT scans of the brain, duplex 
scanning
 
of the carotid arteries, and a cardiac analysis that included
 
standard 12-lead 
electrocardiography and, if indicated, 24-hour electrocardiographic
 
monitoring and 
echocardiography. All patients were examined
 
within 72 hours, and 42 of them were examined 
within 24 hours
 
after onset of neurological symptoms. In patients with stroke
 
in the carotid 
territory, the symptoms were further subdivided
 
according to the presence of cortical signs 
(aphasia, dysgraphia,
 
dyslexia, or hemianopia) or one of the following lacunar syndromes:
 
pure 
motor hemiplegia, pure sensory stroke, or sensorimotor
 
stroke.
22
 The CT scans were reviewed by 
at least two neurologists
 
without knowledge of the clinical features or the results of
 
the 
biochemical studies. Cerebral infarctions were classified
 
according to location and vascular 
territory.
23
 Subcortical
 
infarctions were further classified as small ( 15 mm) or large
 
(>15 mm).
 
 
Apart from the neurological history, the following risk factors
 
were recorded: smoking habits, 
hypercholesterolemia (history
 
of hypercholesterolemia and/or fasting total cholesterol level
 
>6.5 
mmol/L),
24
 hypertension (history of hypertension and/or
 
systolic blood pressure >160 mm Hg 
and/or diastolic blood pressure
 
>90 mm Hg, treated or not), diabetes mellitus (history of
 
diabetes 
mellitus type I or II and/or a random blood glucose
 
of 8.0 mmol/L together with an HbA1c level 
of 6.3%, treated
 
or not),
25
 atrial fibrillation (history of atrial fibrillation
 
and/or atrial fibrillation 
on electrocardiogram), and a history
 
of intermittent claudication, angina pectoris, prior 
myocardial
 
infarction, or prior vascular surgery (carotid, coronary, aortic
 
bifurcation, or 
peripheral vascular surgery). We carefully recorded
 
the medication that was used in the days 
before the stroke and
 
during the study period, distinguishing patients without antithrombotic
 
or 
anticoagulant therapy and those using cyclooxygenase inhibitors,
 
heparin, oral anticoagulant 
therapy, or a combination of these.
 
Patients with atrial fibrillation were heparinized and received
 
oral anticoagulant treatment. In patients with aspirin for secondary
 
prevention after stroke or 
myocardial infarction, treatment
 
was continued during the study period. The other patients were
 
included in the IST and were randomized for treatment with aspirin,
 
heparin, both, or neither.
26
 
Stroke severity was assessed by
 
means of the modified Rankin scale
27
 on admission, and 
functional outcome
 
was assessed by means of this scale at 3-month follow-up.
 
 
The routine laboratory investigations included hemoglobin, hematocrit, leukocyte,
 
erythrocyte 
and platelet counts, erythrocyte sedimentation rate,
 
blood urea, creatinine, fasting cholesterol and 
glucose, and
 
liver enzymes.
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Exclusions 
Patients were excluded if they required invasive investigations, in
 
particular angiography, during 
the study period. Also excluded
 
were patients with vasculitis, renal disease (creatinine >200
 
µmol/L), unstable angina pectoris (recent onset of class
 
III to IV chest pain according to the 
Canadian Heart Association, in
 
the absence of an increase in the MB fraction of plasma 
creatinine
 
kinase), or macroscopic hematuria.
 
 
Urine Measurements 
Two to eight 6-hour samples of urine were collected during the first
 
72 hours after the onset of 
symptoms, starting as soon as possible
 
after admission to the hospital. The average delay 
between onset
 
of symptoms and the start of urinary sampling was 14±12
 
hours. The volume of 
each urine sample was recorded, and the creatinine
 
concentration was measured. Samples of 50 
mL, containing 1 mmol/L
 
4-hydroxy-TEMPO as an antioxidant, were stored in the refrigerator
 
until they were frozen every 6 hours and stored at -70°C
 
until extraction. Analytical 
measurements related to eicosanoid
 
biosynthesis were performed in a manner blinded to the 
pharmacological
 
treatments.
 
 
Immunoreactive 11-dehydro-TXB2 and 8-epi-PGF2  were extracted
 
from 10-mL aliquots of each 
coded urine sample (the pH was adjusted
 
to 4.0 with formic acid) on SEP-PAK C18 cartridges 
(Waters Associates)
 
and eluted with ethyl acetate. The eluates were subjected to
 
silicic acid 
column chromatography and further eluted with benzene/ethyl acetate/methanol
 
(60:40:30, 
vol/vol). The overall recovery averaged 74.5±5.1%.
 
The eluates were dried, recovered with 5 mL 
of buffer, and assayed
 
in the radioimmunoassay system at a final dilution ranging from
 
1:30 to 
1:1000 for 11-dehydro-TXB2 and 1:30 to 1:1000 for 8-epi-PGF2 .
28 29
 The urinary excretion rate 
of 11-dehydro-TXB2 and 8-epi-PGF2
 
was expressed as picomoles per millimole of creatinine.
 
 
Validation of the 8-epi-PGF2  assay in urine was provided by
 
comparison of values obtained by 
thin-layer chromatography/enzyme
 
immunoassay (with the same antibody used in the present 
study)
 
with an independent analytical approach, negative ion chemical
 
ionization–gas 
chromatography/mass spectrometry. An excellent correlation
 
between the two methods was 
obtained: r=.99, n=9, P<.001,
 
slope of regression line=1.01. Moreover, 12 urine samples were
 
extracted and measured by radioimmunoassay with the use of two
 
different antisera with 
different cross-reactivities toward 8-epi-PGE2,
 
and similar values were obtained (r=.99, n=12, 
P<.001).
29 
 
Statistical Analysis 
Mean values between groups were compared with the use of Student's
 
t test. Values of P<.05 
were considered statistically significant.
 
For time series analysis, all potential prognostic 
variables
 
were dichotomized by their medians or trichotomized at the P33
 
and P67 when deemed 
appropriate. In an exploratory analysis,
 
the relationship between the levels of 8-epi-PGF2  and 
11-dehydro-TXB2 in
 
consecutive urine samples and these variables was analyzed with
 
ANOVA 
for repeated measures with the use of the BMDP program
 
9d.
30
 The difference between mean 
levels of 8-epi-PGF2  and
 
11-dehydro-TXB2 for a certain variable was considered clinically
 
meaningful when there was a statistically significant difference
 
(P<.05; ANOVA) for at least two 
consecutive samples or for
 
a total of four samples in the series in the same direction.
 
In a logistic 
regression analysis with stepwise forward selection
 
of variables, we identified those factors that 
were independently
 
related with repeatedly increased (ie, more than once) 11-dehydro-TXB2 
levels.
 
 
 
 
 
   Results  
  
In the majority of patients (42) sampling started within 24
 
hours after stroke onset, and in 28 
sampling started within
 
12 hours. Two to eight consecutive 6-hour urinary samples were
 
obtained 
during the first 48 hours after admission. Thirty patients
 
were treated with cyclooxygenase 
inhibitors, 26 used aspirin,
 
1 aspirin and the NSAID indomethacin, and 3 NSAIDs only, of
 
whom 
1 used ibuprofen, 1 diclofenac, and 1 naproxen. Three patients
 
with NSAIDs were using this 
drug before onset of stroke, and
 
during the study it was continued. The patient on diclofenac 
started
 
with this medication on admission. Of the 27 patients on aspirin,
 
13 were using it as 
secondary prevention before the onset of the
 
current stroke, and it was continued during the 
study. Twelve patients
 
started with aspirin at the beginning of the study, of whom
 
11 received it 
in accordance with the IST and 1 after denying
 
consent for randomization in the IST. In 2 
patients who had
 
received aspirin from the general practitioner and who denied
 
consent for 
randomization in the IST, the medication was discontinued
 
during the sampling period. Thus, a 
total of 17 patients were
 
using antiplatelet medication before the start of the study,
 
which was 
continued in 15 and stopped in 2, and 13 patients
 
started with antiplatelet medication at the 
beginning of the
 
study. No difference was found in excretion levels of both eicosanoids
 
between 
patients who were on antiplatelet medication before
 
the beginning of the study and patients who 
started on admission,
 
nor was a difference found between patients on aspirin and patients
 
on 
NSAIDs. Therefore, all patients using cyclooxygenase inhibitors
 
before and/or during the 
sampling period were compared with
 
patients without cyclooxygenase inhibitors.
 
 
Compared with thromboxane excretion levels of control subjects
 
from our previous study 
(mean+2 SD=251 pmol/mmol creatinine),
1 
40 patients (65%) had at least one sample with an 
increased
 
excretion rate of 11-dehydro-TXB2, while in 32 (52%) increased
 
metabolite excretion 
was found repeatedly. For patients treated
 
with cyclooxygenase inhibitors at the time of study, 
the corresponding
 
percentages were 53% and 40%, respectively. In untreated patients
 
these 
percentages were higher (P=.1), at 75% and 63%, respectively.
 
 
In 30 patients treated with cyclooxygenase inhibitors (most
 
of whom were taking 300 mg of 
aspirin daily), 197 samples were
 
obtained. Urinary 11-dehydro-TXB2 averaged 221±207 
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pmol/mmol
 
creatinine (mean±SD; range, 13 to 967) in these samples.
 
In 186 samples of 32 
untreated patients, 11-dehydro-TXB2 averaged
 
392±392 (range, 26 to 2533). The difference was 
statistically
 
significant (P<.001). No statistically significant difference
 
was found in the levels of 
8-epi-PGF2 , with mean values of 74±42
 
(range, 14 to 206) in patients on cyclooxygenase 
inhibitors
 
and 83±65 (range, 24 to 570) in untreated patients.
 
 
Values of 8-epi-PGF2  were only modestly correlated with 11-dehydro-TXB2
 
excretion, with a 
coefficient of .40 (P<.001). The correlation
 
coefficient was .35 in patients treated with 
cyclooxygenase inhibitors
 
and .41 (P<.001) in untreated patients.
 
 
Fig 1  shows mean values and 95% confidence intervals of both
 
eicosanoids of all patients for 
each time period. The level
 
of 8-epi-PGF2  fluctuated at approximately 80 pmol/mmol 
creatinine.
 
No consistent pattern was found in its excretion over time.
 
In contrast, excretion of 
11-dehydro-TXB2 was increased in the first
 
period after stroke onset, with a subsequent decline 
thereafter. When
 
medication was taken into account, most of this decline could
 
be attributed to 
cyclooxygenase inhibition. As shown in Fig
 
2 , patients treated with cyclooxygenase inhibitors 
had a swift and
 
constant decrease in 11-dehydro-TXB2 excretion to normal values
 
in the first 24 
hours after stroke onset. Metabolite excretion
 
remained constant in the subsequent periods. In 
contrast, patients
 
without cyclooxygenase inhibition had repeatedly increased values
 
of 11-
dehydro-TXB2 excretion. No difference was found in 8-epi-PGF2  excretion
 
between patients 
with and without cyclooxygenase inhibitors.
 
 
 
 
 
View larger version (41K): 
[in this window] 
[in a new window] 
   
Figure 1. Mean values and 95% confidence intervals of 
urinary excretion of 11-dehydro-TXB2 and 8-epi-PGF2  
for each time period in hours after onset of stroke. Line 
indicates the mean+2 SD of control subjects. 
 
 
 
 
Figure 2. Mean values of urinary excretion of 11-
dehydro-TXB2 and 8-epi-PGF2  for patients with and 
patients without cyclooxygenase inhibitors for each time 
period in hours after onset of stroke. Line indicates the 
mean+2 SD of control subjects. 
View larger version (38K): 
[in this window] 
[in a new window] 
   
 
In a first approach to evaluate univariately the relationship
 
between baseline characteristics, risk 
factors, stroke characteristics,
 
and medication on the one hand and level of eicosanoids on the
 
other, we explored differences in peak eicosanoid excretion.
 
Table 1  shows the mean±SD value 
of peak eicosanoid excretion
 
for demographic characteristics and cardiovascular risk factors.
 
Higher values of 11-dehydro-TXB2 were found in patients with
 
atrial fibrillation and in patients 
with congestive heart failure.
 
For 8-epi-PGF2  no differences in excretion rates were found.
 
Table 2  shows the mean±SD of peak eicosanoid excretion
 
for stroke characteristics and 
medication. Patients with a cortical
 
syndrome had higher peak values of 11-dehydro-TXB2 than 
patients
 
with a lacunar stroke or a stroke confined to the vertebrobasilar
 
territory. Higher peak 
values of 11-dehydro-TXB2 were also found
 
in patients with severe strokes. Patients using 
cyclooxygenase-inhibiting drugs
 
had significantly lower peak values of 11-dehydro-TXB2. 
Again,
 
for 8-epi-PGF2  no differences in excretion rate were found.
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Table 1. Maximum 8-Epi-PGF2  and 11-Dehydro-TXB2 Production for 
Demographic Characteristics and Cardiovascular Risk Factors 
 
 
 
View this 
table: 
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window] 
   
Table 2. Maximum 8-Epi-PGF2  and 11-Dehydro-TXB2 Production for 
Stroke Characteristics and Medication 
 
As a second step, we performed the time series analysis described
 
in "Subjects and Methods." In 
this analysis, 8-epi-PGF2  levels
 
were found to be elevated in patients with atrial fibrillation.
 
Higher levels of 11-dehydro-TXB2 were found in patients with
 
a history of intermittent 
claudication, atrial fibrillation,
 
cortical infarctions, severe strokes, and poor stroke outcome
 
and 
in patients with a urinary catheter. Patients with a history
 
of myocardial infarction and patients 
using cyclooxygenase inhibitors
 
had lower values of 11-dehydro-TXB2. Because patients with a 
urinary
 
catheter had increased 11-dehydro-TXB2 levels, we examined whether
 
this could be 
explained by urinary tract damage with subsequent
 
hemorrhage and platelet activation. None of 
the patients had
 
macroscopic hematuria. Furthermore, no relationship was found
 
between level of 
microscopic hematuria and level of 11-dehydro-TXB2.
 
 
In a multiple logistic regression analysis, repeatedly increased
 
11-dehydro-TXB2 levels were 
related to severity of stroke on
 
admission, presence of atrial fibrillation, and antiplatelet
 
treatment. Coumarin and heparin treatment were not associated
 
with repeatedly increased 11-
dehydro-TXB2 levels.
 
 
Finally, repeatedly increased thromboxane metabolite excretion
 
was not a statistically significant 
independent prognostic factor
 
for outcome when added to stroke syndrome or stroke severity
 
in a 
multiple logistic regression model, probably because of
 
the rather small size of this study.
 
 
 
 
 
   Discussion  
  
In this study, 65% of patients with acute ischemic stroke had
 
at least one period of enhanced 
thromboxane biosynthesis, while
 
in half of the patients this occurred repeatedly. This is slightly
 
less than the 85% and 61%, respectively, we found in our previous
 
study.
2
 However, in the 
current study almost half of the patients
 
received cyclooxygenase inhibitors. For untreated 
patients the
 
results were in accordance with our previous findings.
 
 
In contrast, levels of 8-epi-PGF2  seemed rather low, with an
 
average of approximately 80 
pmol/mmol creatinine. Although no
 
control subjects were used in this study, normal values of 8-
epi-PGF2
 
of 50.7±5.7 and 70.5±33.9 pmol/mmol creatinine
 
were reported in other studies.
16
 
29
 
We found only a weak correlation
 
between levels of 11-dehydro-TXB2 and 8-epi-PGF2 . 
Whereas levels
 
of 11-dehydro-TXB2 decreased in time in patients with cyclooxygenase-
inhibiting
 
drugs, no changes in urinary 8-epi-PGF2  excretion were found
 
in these patients. 
Although some studies suggest that 8-epi-PGF2
 
can be formed in a cyclooxygenase-dependent 
fashion from human platelets,
16 18
 our results indicate that in a clinical condition in which
 
platelets are clearly activated, there are no concurrent changes
 
in 8-epi-PGF2  formation and 
excretion. Moreover, no significant
 
differences in 8-epi-PGF2  were found between patients with 
and
 
without cyclooxygenase-inhibiting drugs, again indicating that
 
levels of 8-epi-PGF2  found 
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in patients with acute ischemic stroke
 
are probably not produced in a cyclooxygenase-dependent 
fashion.
 
In univariate analysis, no factors that were found to be associated
 
with 11-dehydro-TXB2 
production were also related to 8-epi-PGF2
 
excretion. Only in patients with atrial fibrillation 
was 8-epi-PGF2
 
found increased in two consecutive periods in the time series
 
analysis.
 
 
Increased levels of 8-epi-PGF2  excretion were found after thrombolytic
 
therapy in patients with 
acute myocardial infarction.
16
 These
 
findings suggest that the source of 8-epi-PGF2  under these 
conditions
 
is free radical–catalyzed lipid peroxidation associated with occlusion/reperfusion. 
Enhanced formation of 8-epi-PGF2  might
 
be expected in patients with acute stroke, a condition 
in which
 
formation of free radicals occurs. However, in our patients
 
no evident peaks of 8-epi-
PGF2  excretion could be detected.
 
In stroke patients it is difficult to predict if and when 
reperfusion occurs.
 
Still, we should have detected significant changes in 8-epi-PGF2
 
excretion if 
they occurred, since we collected 6-hour samples
 
of urine during the time in which reperfusion 
might be expected
 
in the majority of patients.
31
 Alternatively, increased oxidant
 
stress might 
occur as an early transient event, largely missed
 
by the timing of our urine sampling, or else the 
signal-to-noise
 
ratio might be too small to be detected at a distance from its
 
source.
 
 
Increased 11-dehydro-TXB2 excretion was univariately associated
 
with a history of intermittent 
claudication or atrial fibrillation,
 
the presence of a urinary catheter, cortical infarctions, severe
 
strokes, and worse outcome. A urinary catheter may induce urinary
 
tract damage with subsequent 
hemorrhage and possibly platelet
 
activation. In our study a urinary catheter was indeed 
associated
 
with enhanced 11-dehydro-TXB2 level but also with stroke severity
 
and outcome. In 
our ward, patients with severe strokes are always
 
given a urinary catheter, which explains the 
relation to severity
 
and outcome. None of the patients had macroscopic hematuria,
 
and no 
association was found between the level of microscopic
 
hematuria and the level of urinary 11-
dehydro-TXB2. Therefore,
 
it is unlikely that urinary 11-dehydro-TXB2 levels were the
 
result of 
urinary tract damage. Data on the number of leukocytes
 
and epithelial cells in the urine were 
incomplete, and therefore
 
the contribution of these cells to urinary 11-dehydro-TXB2 could
 
not 
be evaluated.
 
 
The other factors associated with increased thromboxane production—ie, atrial fibrillation, large 
subcortical and cortical infarctions,
 
stroke severity and outcome, and the absence of 
cyclooxygenase
 
inhibitors—may reflect the fact that atrial fibrillation is more likely to cause 
large cortical infarctions that are
 
mostly severe. Moreover, patients with atrial fibrillation usually
 
receive heparin and coumarin treatment and not cyclooxygenase
 
inhibitors. However, in a 
multiple logistic regression analysis,
 
atrial fibrillation, stroke severity, and cyclooxygenase 
inhibition
 
were independently related to the level of urinary 11-dehydro-TXB2.
 
 
An important remaining question is whether a causal relationship
 
exists between the extent and 
duration of platelet activation,
 
as reflected by the level of 11-dehydro-TXB2 excretion, and stroke
 
severity and outcome. In this study repeatedly increased thromboxane
 
production was not a 
statistically significant independent prognostic
 
factor for outcome when added to stroke 
syndrome or stroke severity
 
in a multiple logistic regression model, probably because of
 
the 
rather small size of our study. However, the results of
 
trials that evaluate the value of antiplatelet 
therapy in acute
 
ischemic stroke, of which the IST
26
 and the Chinese Acute Stroke
 
Trial
32
 are by 
far the largest, may contribute to define the
 
role of platelet activation in this setting. Preliminary 
results
 
of these studies indicate that aspirin has a beneficial effect,
 
albeit small, in acute ischemic 
stroke.
32
 
33 
 
We conclude that during the first few days after an acute ischemic
 
stroke (1) platelet activation 
occurs repeatedly in a cyclooxygenase-dependent
 
fashion; (2) platelet activation is not associated 
with concurrent
 
changes in F2-isoprostane biosynthesis; (3) platelet activation
 
is independently 
associated with stroke severity and atrial
 
fibrillation; and (4) F2-isoprostane biosynthesis is 
largely
 
independent of platelet cyclooxygenase activity.
 
 
 
 
 
   Selected Abbreviations and Acronyms  
  
11-dehydro-TXB2 = 11-dehydro-thromboxane B2 
8-epi-PGF2  = 8-epi-prostaglandin
 
F2  
IST = International Stroke Trial 
NSAIDs = nonsteroidal
 
anti-inflammatory drugs 
TXA2 = thromboxane A2 
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